Eastgate Biotech Stock Forecast, Price & News

+0.00 (+40.00 %)
(As of 04/13/2021 02:00 PM ET)
Today's Range
Now: $0.00
50-Day Range N/A
52-Week Range
Now: $0.00
Volume21,000 shs
Average Volume152,505 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil. Eastgate Biotech Corp. has collaboration with Biotech Corp. to develop a vaccine against COVID-19. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was founded in 1999 and is based in Toronto, Canada.
Eastgate Biotech logo

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolOTCMKTS:ETBI
Previous SymbolOTCMKTS:ESAQ
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable


Looming China extradition deal worries Uighurs in Turkey
March 10, 2021 |  in.finance.yahoo.com
Cirrus Adds Aubrey McCarthy as Director of Client Success
March 10, 2021 |  sg.finance.yahoo.com
No Ofcom action over Maitlis's Cummings remarks on Newsnight
March 10, 2021 |  in.finance.yahoo.com
Former NIH Executive John J. McGowan, PhD, Joins Guidehouse
March 10, 2021 |  ca.finance.yahoo.com
Eastgate Biotech Corp Stock , ETBI
December 25, 2020 |  markets.businessinsider.com
News for Eastgate Biotech Corp
December 24, 2020 |  markets.businessinsider.com
Eastgate Biotech Corp.
May 21, 2020 |  www.barrons.com
Eastgate Biotech securities suspended from trading by SEC
February 24, 2020 |  seekingalpha.com
EastGate Spreads Wings in Bidding Au Revoir to ‘19
December 30, 2019 |  www.baystreet.ca
See More Headlines


Overall MarketRank

0.52 out of 5 stars

Medical Sector

1519th out of 2,019 stocks

Biotechnology Industry

79th out of 145 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.00 (+40.00 %)
(As of 04/13/2021 02:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ETBI News and Ratings via Email

Sign-up to receive the latest news and ratings for ETBI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Eastgate Biotech (OTCMKTS:ETBI) Frequently Asked Questions

What stocks does MarketBeat like better than Eastgate Biotech?

Wall Street analysts have given Eastgate Biotech a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eastgate Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Eastgate Biotech's stock price been impacted by Coronavirus?

Eastgate Biotech's stock was trading at $0.0077 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ETBI stock has decreased by 54.5% and is now trading at $0.0035.
View which stocks have been most impacted by COVID-19

Who are Eastgate Biotech's key executives?

Eastgate Biotech's management team includes the following people:
  • Ms. Rosella C. Perri, CEO, Sec., Treasurer & Director (Age 53)
  • Dr. Mirjana Hasanagic, VP of Natural Products (Age 54)
  • Mr. William D. Abajian, Vice Chairman, Pres & COO (Age 63)
  • Dr. Joseph Schwarz Ph.D., Chief Scientific Officer (Age 65)
  • Dr. Michael Weisspapir, Chief Medical Officer (Age 63)

Who are some of Eastgate Biotech's key competitors?

What other stocks do shareholders of Eastgate Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eastgate Biotech investors own include Delcath Systems (DCTHD), Cassava Sciences (SAVA), (APHA), Broadcom (AVGO), Exelixis (EXEL), Immunomedics (IMMU), JPMorgan Chase & Co. (JPM), NeoGenomics (NEO), Nokia (NOK) and PagSeguro Digital (PAGS).

What is Eastgate Biotech's stock symbol?

Eastgate Biotech trades on the OTCMKTS under the ticker symbol "ETBI."

How do I buy shares of Eastgate Biotech?

Shares of ETBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eastgate Biotech's stock price today?

One share of ETBI stock can currently be purchased for approximately $0.00.

How many employees does Eastgate Biotech have?

Eastgate Biotech employs 2 workers across the globe.

What is Eastgate Biotech's official website?

The official website for Eastgate Biotech is www.eastgatebiotech.com.

Where are Eastgate Biotech's headquarters?

Eastgate Biotech is headquartered at 2681 E Parleys Way Ste 204, SALT LAKE CITY, UT 84109-1668, United States.

How can I contact Eastgate Biotech?

Eastgate Biotech's mailing address is 2681 E Parleys Way Ste 204, SALT LAKE CITY, UT 84109-1668, United States. The company can be reached via phone at +1-801-3223401.

This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.